Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Particulate & foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables.

867 FDA drug recalls with this cause, newest first.

These recalls involve visible foreign material - glass, metal, fibers, rubber or other debris - most often found in injectable or liquid products, where nothing besides the intended ingredients should be present. It also includes foreign tablets or capsules found in a bottle of a different product. In an injectable a stray particle can go straight into the bloodstream, which is why a noticeable share of these recalls are Class I.

Class I · High risk

Isovue -300

Presence of Particulate Matter; fibers identified as cellulose and polyvinyl

Terminated Particulate / foreign matter Bracco Diagnostic Inc NDC 0270-1315-67 D-158-2013
Class I · High risk

Isovue -370

Presence of Particulate Matter; fibers identified as cellulose and polyvinyl

Terminated Particulate / foreign matter Bracco Diagnostic Inc NDC 0270-1316-66 D-157-2013
Class II · Moderate risk

traMADOL Hydrochloride Tablets

Adulterated Presence of Foreign Tablets: A customer complaint was received that a bottle of Tramadol HCl Tablets USP 50 mg contained some tablets of Metoprolol Tartrate Tablets USP, 50 mg.

Terminated Particulate / foreign matter Caraco Pharmaceutical Laboratories, Ltd. NDC 57664-377-18 D-089-2013
Class II · Moderate risk

Lidocaine HCl Injection

Presence of Particulate Matter: Report of a vial containing visible particulate matter embedded in the glass wall which has the potential to dislodge resulting in the presence of particulate matter in the product.

Terminated Particulate / foreign matter Hospira, Inc. NDC 0409-4279-02 D-099-2013
Class II · Moderate risk

Propofol Injectable Emulsion

Presence of Particulate Matter: A single visible particulate was observed and confirmed in sample bottles of the recalled lots during retain inspection.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-30 D-1685-2012
Class II · Moderate risk

Atorvastatin Calcium Tablets

Adulterated Presence of Foreign Tablets: A product complaint was received by a pharmacist who discovered an Atorvastatin 20 mg tablet inside a sealed bottle of 90-count Atorvastatin 10 mg.

Terminated Particulate / foreign matter Ranbaxy Inc. NDC 63304-827-90 D-060-2013
Class II · Moderate risk

Propofol Injectable Emulsion

Presence of Particulate Matter: A single visible particulate was observed and confirmed in a sample bottle during retain inspection.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-24 D-1672-2012
Class I · High risk

Trastuzumab Kit containing 1 vial Trastuzumab

Presence of Particulate Matter: One lot of Bacteriostatic Water for Injection, USP diluent vials that were packed with Trastuzumab Kits for investigational use has the potential to contain glass particulates.

Terminated Particulate / foreign matter Genentech Inc NDC 50242-903-69 D-135-2013
Class II · Moderate risk

Levetiracetam Tablets

Adulterated Presence of Foreign Tablets: Pharmaceutical manufacturer may have distributed foreign tablets in bottles of Levetiracetam Tablets, USP 500 mg.

Terminated Particulate / foreign matter Mylan Pharmaceuticals Inc. NDC 0378-5615-05 D-1702-2012
Class II · Moderate risk

OFIRMEV (acetaminophen)

Presence of Particulate Matter: The firm initiated the recall due to visible presence of particulate matter.

Terminated Particulate / foreign matter Cadence Pharmaceuticals NDC 43825-102-01 D-1432-2012
Class III · Low risk

Nexium (esomeprazole magnesium)

Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.

Terminated Particulate / foreign matter ASTRA ZENECA Lp NDC 0186-5040-85 D-1410-2012
Class II · Moderate risk

Paclitaxel Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. D-1682-2012
Class II · Moderate risk

Methotrexate Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 61703-408-41 D-1681-2012
Class II · Moderate risk

Cytarabine Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 61703-303-46 D-1680-2012
Class II · Moderate risk

Carboplatin Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are beig recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 61703-339-50 D-1679-2012